Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod

Jul 26 2023

• By Ayisha Sharma

graphic illustration of kidneys — Chronic Kidney Disease Affects 850 Million People Worldwide • Source: Shutterstock

Related Content

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

Mar 30 2023

Patent Blocks Zydus After Landmark US Approval For Dapagliflozin

Feb 24 2022

More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval

May 04 2021

BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved

Aug 30 2021

Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure

Aug 29 2022

AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition

Jan 10 2023

Related Companies

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Additional Topics

Europe Approvals Companies Regulation Commercial Renal Cardiovascular BioPharmaceutical

More from Genitourinary

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window